← All trials
NCT05005975
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 10, 2021
- Primary completion
- Sep 30, 2023
- Completion date
- Sep 30, 2023
- First posted
- Aug 16, 2021
- Last posted
- Nov 26, 2021
- Enrollment
- 120
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Mitsubishi TanabeLead sponsor
- Mitsubishi TanabeStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.